Douglas Sawyer
Faculty Member
Last active: 7/21/2014

  1. Soluble ST2 as a Diagnostic and Prognostic Marker for Acute Heart Failure Syndromes. Henry-Okafor Q, Collins SP, Jenkins CA, Miller KF, Maron DJ, Naftilan AJ, Weintraub N, Fermann GJ, McPherson J, Menon S, Sawyer DB, Storrow AB (2012) Open Biomark J 2012(5): 1-8
    › Primary publication · 23439880 (PubMed) · PMC3578210 (PubMed Central)
  2. Risk stratification in acute heart failure: rationale and design of the STRATIFY and DECIDE studies. Collins SP, Lindsell CJ, Jenkins CA, Harrell FE, Fermann GJ, Miller KF, Roll SN, Sperling MI, Maron DJ, Naftilan AJ, McPherson JA, Weintraub NL, Sawyer DB, Storrow AB (2012) Am Heart J 164(6): 825-34
    › Primary publication · 23194482 (PubMed) · PMC3511776 (PubMed Central)
  3. Relationship between Uric Acid Levels and Diagnostic and Prognostic Outcomes in Acute Heart Failure. Henry-Okafor Q, Collins SP, Jenkins CA, Miller KF, Maron DJ, Naftilan AJ, Weintraub N, Fermann GJ, McPherson J, Menon S, Sawyer DB, Storrow AB (2012) Open Biomark J : 9-15
    › Primary publication · 24058387 (PubMed) · PMC3777695 (PubMed Central)
  4. Relation of vascular growth factors with CT-derived measures of body fat distribution: the Framingham Heart Study. Kaess BM, Pedley A, Massaro JM, Larson MG, Corsini E, Hoffmann U, Smith HM, Sawyer DB, Vasan RS, Fox CS (2012) J Clin Endocrinol Metab 97(3): 987-94
    › Primary publication · 22170711 (PubMed) · PMC3319207 (PubMed Central)
  5. Neuregulin in cardiovascular development and disease. Odiete O, Hill MF, Sawyer DB (2012) Circ Res 111(10): 1376-85
    › Primary publication · 23104879 (PubMed) · PMC3752394 (PubMed Central)
  6. Geographic variations in heart failure hospitalizations among medicare beneficiaries in the Tennessee catchment area. Ogunniyi MO, Holt JB, Croft JB, Nwaise IA, Okafor HE, Sawyer DB, Giles WH, Mensah GA (2012) Am J Med Sci 343(1): 71-7
    › Primary publication · 21804374 (PubMed) · PMC4074884 (PubMed Central)
  7. Galectin 3 complements BNP in risk stratification in acute heart failure. Fermann GJ, Lindsell CJ, Storrow AB, Hart K, Sperling M, Roll S, Weintraub NL, Miller KF, Maron DJ, Naftilan AJ, McPherson JA, Sawyer DB, Christenson R, Collins SP (2012) Biomarkers 17(8): 706-13
    › Primary publication · 22998064 (PubMed) · PMC3678263 (PubMed Central)
  8. ErbB4 localization to cardiac myocyte nuclei, and its role in myocyte DNA damage response. Icli B, Bharti A, Pentassuglia L, Peng X, Sawyer DB (2012) Biochem Biophys Res Commun 418(1): 116-21
    › Primary publication · 22244893 (PubMed) · PMC3273580 (PubMed Central)
  9. ERBB2 inhibition and heart failure. Cote GM, Sawyer DB, Chabner BA (2012) N Engl J Med 367(22): 2150-3
    › Primary publication · 23190227 (PubMed)
  10. Elevated urinary neutrophil gelatinase-associated lipocalcin after acute heart failure treatment is associated with worsening renal function and adverse events. Collins SP, Hart KW, Lindsell CJ, Fermann GJ, Weintraub NL, Miller KF, Roll SN, Sperling MI, Sawyer DB, Storrow AB (2012) Eur J Heart Fail 14(9): 1020-9
    › Primary publication · 22733980 (PubMed) · PMC3423948 (PubMed Central)